Nor-qd and Lacrimal duct neoplasm - a phase IV clinical study of FDA data
Summary:
We study 105 people who take Nor-qd (norethindrone) or have Lacrimal duct neoplasm. No report of Lacrimal duct neoplasm is found in people who take Nor-qd.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Nor-qd?
Nor-qd has active ingredients of norethindrone. It is often used in birth control. eHealthMe is studying from 80 Nor-qd users. Check the latest studies of Nor-qd.
What is Lacrimal Duct Neoplasm?
Lacrimal duct neoplasm (an abnormal mass of tissue of lacrimal duct) is found to be associated with 7 drugs and 61 conditions by eHealthMe. Check the latest studies of Lacrimal duct neoplasm.
No report is found.
Do you take Nor-qd and have Lacrimal duct neoplasm?
- Check whether Lacrimal duct neoplasm is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Nor-qd:
- Nor-qd (80 reports)
Lacrimal duct neoplasm treatments and more:
- Lacrimal duct neoplasm (25 reports)
How severe was Lacrimal duct neoplasm and when was it recovered:
Expand to all the drugs that have ingredients of norethindrone:
Browse all side effects of Nor-qd:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Lacrimal duct neoplasm:
Browse all the conditions that are associated with Lacrimal duct neoplasm:
How the study uses the data?
The study uses data from the FDA. It is based on norethindrone (the active ingredients of Nor-qd) and Nor-qd (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Myrbetriq and Insomnia for Men aged 20-29 - 12 seconds ago
- Myrbetriq and Can'T Sleep for Men aged 20-29 - 12 seconds ago
- Myrbetriq and Agrypnia for Men aged 20-29 - 13 seconds ago
- Myrbetriq and Insomnia Concerns for Men aged 20-29 - 13 seconds ago
- Myrbetriq and Difficulty Falling Asleep for Men aged 20-29 - 13 seconds ago
- Myrbetriq and Sleeplessness for Men aged 20-29 - 14 seconds ago
- Myrbetriq and Inability To Sleep for Men aged 20-29 - 14 seconds ago
- Myrbetriq and Sleeping for Men aged 20-29 - 14 seconds ago
- Myrbetriq and Sleep Aid for Men aged 20-29 - 15 seconds ago
- Myrbetriq and Insomnolence for Men aged 20-29 - 15 seconds ago